ANDA For Generic Epilepsy Drug Spurs Suit Against IVAX

Law360, New York (September 24, 2005, 12:00 AM EDT) -- Belgian drugmaker UCB Societe Anonyme has sued IVAX Corporation in federal court, seeking protection of its popular epilepsy drug Keppra from generic competition before the expiration of its patent.

The suit alleges Florida-based IVAX infringed its patent by filing an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration to produce Levetiracetam, the active ingredient in Keppra.

Compelled by the Hatch-Waxman Act, IVAX informed UCB of its intentions to produce the 250 mg 500 mg and 750 mg tablets through a notice of...
To view the full article, register now.